EXECUTIVE SUMMARY

The World’s Most Advanced Single Use Toothbrushes and more!

Clean Bite™ I & Clean Bite™ II

CBI is prepared to be Acquired Outright, in an M&A, or through licensing and distribution agreements

Objectives Completed:

Clean Bite, LLC, transitioned in March 2024 to Clean Bite, Inc., a Delaware corporation with patents in the United States, 25 European countries, and India. The company’s IP is devoted to oral hygiene for people and companion pets. The product line spans from the on-the-go single-use Clean Bite™ I to the Clean Bite™ II for companion pets, eliminating the pet owner’s need for brushing.

Clean Bite™ products are notably different in design and composition in their chemical formulations and geometric designs. When combined, each patent’s IP affords a broad application. Strengthening these iterations is the collaboration between Clean Bite, Inc. and Livionex, Inc. of Los Gatos, CA., makers of LivFresh Dental Gel toothpaste. Among its accolades and verified test results, LivFresh is the only OTC dentifrice in the EU awarded a CE Mark recommended for preventing and treating gingivitis and periodontitis. LivFresh Dental Gel toothpaste, in verified tests, removes 250% more plaque than the touted gold standard. These two patented IPs are unmatched in the industry by replacing the need to scale the tooth surface.  

The ability of Clean Bite™ products to act as a delivery system for API (e.g., vitamins, therapeutics, medications, and oral vaccines) sets the bar even higher. Clean Bite’s approach to providing oral hygiene to populations at any time, anywhere, without the need for water, brush, or paste, is meant to improve oral health globally. Operating on the same principles, the Clean Bite™ product line was expanded to include companion pets with a U.S. patent filing in February 2019, continuing with international filings in 2021. Clean Bite, Inc. has 28 issued international patents in the United States of America, Europe, the EU, and India.

Market Recognition and Strategy:

Clean Bite™ I was designed, prototyped, and patented for an explicit purpose: invent a product that the disabled could use without the need for a caregiver. That required something that would brush teeth just by chewing it and deliver a dentifrice for cleaning and fresh breath, then dissolve and be swallowed when finished. The goal was accomplished, and unwittingly, the intended market, a subset of a subset, opened ubiquitous markets in waiting.

Clean Bite™ II followed the same development path but used criteria contrary to the often-hard fracture products that produced shards to scrape plaque off the tooth surface. Clean Bite turned the table by creating a soft and gentle brush on the teeth’s enamel and gums without pointed bristles. This was possible because of LivFresh Dental Gel toothpaste, which dissolves the bonding compound that holds plaque to the tooth’s surface at the molecular level. This means eliminating course abrasion of the tooth enamel and unintended lacerations of the gums.   

Our patent attorney observed this and questioned why a human application was not being considered. What followed were design adaptations that would accommodate young children and adults who are physically challenged or may have aversions to brushing, such as those on the Autism spectrum.

International Collaboration:

Clean Bite, Inc. has developed products and created defensible IP in diversified markets across North America, Europe, and India. The human population in the countries where the IP is patented is 2.5 billion.

Pet Populations: Data sourced: FEDIAF European Pet Food

                    Dogs           Cats

U. S. A.       90.0 M        74.1  M

Brazil         55.0 M       168.0 M

Canada        7.9 M         85.0 M

Europe     106.4 M       129.1 M

Totals:      259.3 M       456.2 M

The dog and cat populations number around 715.5 million, including Brazil, where the opportunity may be in stand-alone licensing.

Equity funding is a potential prospect for Clean Bite, Inc., but so is an M&A inclusive of all IP. Divestiture or Licensing separate markets may be more feasible, presenting better revenues and a dedicated purpose. The following could be seen in one scenario.

• General human markets such as FMCP, institutional, government, and NGO sales
• Companion pet markets inclusive of all patented jurisdictions and beyond
• Special purpose human market with specific applications related to Neglected Tropical Diseases (NTDs). This segment may be a carveout of Africa.

Pharmaceutical firms are interesting because India is often called “The World’s Pharmacy.” Although oral hygiene is the first engagement for people and pets, delivering APIs is seen as a driver in response to human needs in combating epidemics and pandemics. If the developing world is accustomed to using Clean Bite™ products, adaptation to oral vaccines can respond to urgency. The goal is not the control of Clean Bite, Inc.; it is the proliferation of products that benefit humanity.

Clean Bite, Inc. is soliciting discussions at the corporate or investor level, which may yield collaboration beneficial to both parties.